38 results about "Fat mass" patented technology

The present invention provides a fat mass simulated structure comprising: a granular material having a push-in strength at 10°C of 2×103 N / m2 or more; and an ionic cross-linked polymer which is cross-linked by ions. The granular material has a volume average grain size of 50 μm to 500 μm; the granular material contains vegetable oil at 30 mass% or more with respect to the entire granular material, the vegetable oil having an unsaturated fatty acid ratio of 50 mass% or more and has a melting point of 0°C or less; and the granular material is in liquid form at 35°C and in solid form at 10°C. The present invention also provides: a method for producing a fat mass simulation structure; and a meat substitute.

The invention provides a health plan making method, a health plan making device and electronic equipment, which can be applied to the field of electronic equipment. In the technical scheme provided by the invention, the electronic equipment obtains a target weight reduction rate proportion of a user and a current body weight of the user, the target weight reduction rate proportion is a weight reduction rate proportion expected by the user, and the weight reduction rate proportion is a proportion of the body weight reduced in a first unit duration in the current body weight; determining the weight loss fat content corresponding to the target weight loss rate proportion, wherein the weight loss fat content is the proportion of the fat mass in the reduced body weight to the reduced body weight; and based on the weight loss fat content corresponding to the target weight loss rate ratio, the target weight loss rate ratio, the current body weight of the user, the fat calorie per unit weight and the lean body calorie per unit weight, determining a calorie gap of the user in the second unit time length, thereby providing a matched fat loss exercise plan for the user.

Administration of certain chromium complexes in combination with a starch provide unexpected benefits regarding increasing amino acid absorption, protein synthesis, exercise tolerance, lean muscle mass, skeletal muscle hypertrophy, muscle power, muscle endurance, muscle strength, FSR, and decreasing delayed onset muscle soreness, muscle protein breakdown, and fat mass.

The present invention relates to a transgenic plant having increased biomass, yield, and / or abiotic stress tolerance. In particular, the present invention relates to a transgenic plant or plant cell into which a nucleic acid molecule encoding an RNA demethylase FTO (fat mass associated with obesity) protein is introduced. The present disclosure also provides methods of producing plants having increased biomass, yield, and / or abiotic stress tolerance.

The present disclosure relates to a method of preventing or treating a disease or disorder in a subject in need thereof, wherein administration of a composition of the present disclosure is effective to result in an increase of energy expenditure in the subject. The present disclosure provides a method of reducing fat mass and / or improving glycemic control in a subject in need thereof. The present disclosure provides a method of promoting weight loss and weight maintenance. The present disclosure provides a method of maintaining lean mass. Compositions for use in the methods include a compound of formula (I), (II), or (III), or pharmaceutically acceptable salts thereof, or in combination with a compound selected from the group consisting of an ACC2 inhibitor and an incretin mimetic.

The present invention provides methods of using non-naturally occurring melanocortin analogs to increase body weight and / or increase food consumption in a subject having a kidney disease and / or a liver disease (e.g., chronic kidney disease, renal failure, non-alcoholic fatty liver disease (NAFLD)). Also provided are methods of stimulating appetite in a subject via administration of a non-naturally occurring melanocortin analogue. The non-naturally occurring melanocortin analogs may be present in pharmaceutical compositions and delivered via parenteral administration (e.g., subcutaneous injection). The methods improve appetite, increase food consumption, increase body weight, muscle mass, and / or fat mass in the subject.

Disclosed herein are therapeutic uses of myostatin-selective inhibitors, such as myostatin-selective inhibitors, for treating metabolic disorders, such as obesity. Data presented herein support the notion that selectively targeting myostatin without inhibiting Activin A can achieve equivalent or enhanced efficacy when used in conjunction with a GLP-1 receptor agonist in improving body composition, as compared to broadly antagonizing the ActRII pathway in conjunction with a GLP-1 receptor agonist. Administration of a myostatin-selective inhibitor can prolong the effect of semaglutide on fat mass loss. Moreover, administration of a myostatin-selective inhibitor can elicit positive effects on bone in all parameters evaluated, indicating that diet- or inflammation-induced bone atrophy may be prevented by selective inhibition of the myostatin pathway.

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

1. The name of the design product: liver fat measuring instrument. 2. The use of the design product: for detecting and evaluating liver fat. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

Provided herein are methods of reducing body weight and / or fat mass in a subject in need thereof relative to a control. In some embodiments, the present technology comprises a method of treating, preventing, or reducing body weight gain after a weight loss in a subject in need thereof. The methods comprise administering a non-naturally occurring melanocortin analog to the subject.

Systems and methods for treating cellulite, including apparatus applying or methods involving separating a membrane to eliminate or reduce cellulite appearance. In one method, an interventional tool is placed between tissue layers to act and treat septums connecting the tissue layers containing fat deposits therebetween.

The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and / or luteinizing hormone / choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and / or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and / or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and / or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and / or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and / or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and / or primary hyperparathyroidism.

Provided are a fat mass-simulating structure, a method for producing the same, and a meat substitute, comprising: granules that contain oil / fat, are solid at 10°C and liquid at 35°C; an edible ion-crosslinkable polymer crosslinked with cations; and a polyvalent metal salt having a solubility in water at 20°C of 1 g / 100 g or less. The volume average particle diameter of the granules is 50-500 μm.

The invention relates to the technical field of health assessment, in particular to an intelligent assessment method based on the nutrition state of leukemia children in the chemotherapy period. The method comprises the steps of obtaining the daily weight, muscle mass, fat mass and nutrition intake of a child patient in a chemotherapy period, determining an absorption capacity coefficient based on the change of the nutrition intake and the weight, determining a reserve capacity coefficient for converting nutrition intake into effective reserve in the period based on the change of the muscle mass and the change of the fat mass in adjacent days in the period, and determining a nutrition state index by combining the absorption capacity coefficient and the reserve capacity coefficient, determining a nutrition evaluation coefficient according to the nutrition state indexes of all the time periods of the chemotherapy period before the current moment, and performing risk analysis based on the nutrition evaluation coefficient. The method can more comprehensively and reliably evaluate the nutrition state of the child patient in the chemotherapy period, and improves the accuracy of nutrition state evaluation.

The invention discloses a whole-body multi-end multi-frequency accurate visceral fat measuring method and device, and the method comprises the steps: configuring electrode pairs which comprise four groups of electrode pairs connected with four limbs and four groups of electrode pairs connected with the abdomen, and enabling sampling electrodes of the four groups of electrode pairs on the abdomen to be distributed at four points, the exciting electrodes of the four groups of electrode pairs on the abdomen are positioned outside the sampling electrodes; calculating the amount of non-visceral fat through the four groups of electrode pairs of the four limbs and the body weight; abdomen parameters are calculated through four groups of electrode pairs of the abdomen; and calculating the visceral fat mass according to the non-visceral fat mass and the abdominal parameters. According to the invention, the 16 electrodes are matched with the body weight sensor for measurement, and the non-visceral fat mass of the human body can be more accurately calculated through multi-dimensional and multi-frequency complex impedance measurement, so that the precision of visceral fat mass measurement is improved.

The present disclosure relates to treatment of Hypothalamic Obesity with Tesofensine alone or in combination with a beta-blocker. In particular the disclosure relates to treatments that lead to weight loss, loss of fat mass, in particular visceral fat, and to reduction of symptoms of pre-diabetes in patients suffering from Hypothalamic Obesity.

Disclosed are methods of improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a patient being treated with a GLP-1 receptor agonist, by administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations of a GLP-1 receptor agonist and a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a patient are also provided.

The present invention relates to a body composition analysis method using electroencephalography and an analysis apparatus therefor, wherein information about body composition, such as body water content, protein mass, mineral mass, skeletal muscle mass, body fat percentage, body fat mass, or body mass index (BMI), can be analyzed through electroencephalography signals from a scalp region or an ear region in a stable state with eyes open (EO) or eyes closed (EC). Thus, the present invention can be effectively used for body composition analysis without spatial or temporal constraints.

An object of a system according to an embodiment is to propose training, meals, and a sleep environment that are optimal for an individual user.SOLUTION: A system includes an image analysis part, a body composition meter cooperation part, a meal proposal part, and a sleep proposal part. The image analysis unit analyzes a body shape intended by the user and a photograph of the user. The body composition meter interlocking unit measures a muscle mass and a fat mass based on the data analyzed by the image analysis unit. The meal suggestion unit suggests a meal menu and time based on the data measured by the body composition meter link unit. The sleep suggestion unit suggests a sleep environment based on the data measured by the body composition meter link unit.SELECTED DRAWING: Figure 1

Disclosed are methods of improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, increasing muscle mass, and / or increasing muscle strength in a subject being treated with a GLP-1 receptor agonist, by administering to the subject a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations of a GLP-1 receptor agonist and a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a subject are also provided.

The invention relates to the technical field of biology, in particular to a biomarker related to obesity and application of the biomarker. According to the method, the correlation between the Irisin level in the plasma exosome and animal fat metabolism is utilized, rat models with different obesity degrees are established, and the correlation between the Irisin level in the plasma and the plasma exosome and various fat related indexes is compared and analyzed. The result shows that the Irisin level in the plasma exosome is positively correlated with the body weight, the fat mass, the fat rate and the like and is negatively correlated with the lean mass rate, and the correlation is higher than that of the plasma Irisin level. The Irisin level in the plasma exosome is detected, so that the fat rate of an animal body can be more accurately evaluated, the problems of complicated operation, incapability of quantification, narrow application range and the like of an existing fat detection method are solved, a more effective detection means is provided for related fields, and weight control of obese people is facilitated.

The present invention provides a sugar-restricted, high-fat diet for improving liver disease. In the sugar-restricted, high-fat diet, daily fat intake may be set at 120 g or more based on a real body weight of 50 kg or set at an amount corresponding to 70% or more of the total daily energy intake. The sugar-restricted, high-fat diet can reduce body fat mass and AST, ALT, and γ-GTP levels in nonalcoholic fatty liver disease patients.

A method of obtaining a prognosis for a subject who has or has had leukemia who has been or is being treated with a tyrosine kinase inhibitor (TKI) is described. The method includes determining the levels of one or more of 1) total N6-methyladenosine (m6A), 2) long non-coding RNA (lncRNA) bearing m6A sites, 3) lncRNA-specific m6A, 4) the fat mass and obesity-associated gene (FTO) in a biological sample from the subject; and assigning a poor prognosis or poor TKI responder status to the subject if the level of m6A, lncRNA being m6A sites, lncRNA-specific m6A, and / or FTO is higher than the one or more corresponding control values obtained from a healthy subject. Methods of treating a subject having TKI-resistant leukemia and methods of predicting TKI resistance in a subject having leukemia are also described.

A composition for treating and / or relieving sarcopenia includes Clostridium butyricum M1. A microbial number of Clostridium butyricum M1 ranges from 106 CFU / g to 1012 CFU / g. The composition further includes Bacillus coagulans CC212. Bacillus coagulans CC212 is deposited in Bioresource Collection and Research Center. A deposit number of Bacillus coagulans CC212 is BCRC911233. A microbial number of Bacillus coagulans CC212 is ranges from 106 CFU / g to 1012 CFU / g. A use of the composition is to orally administer the composition to a subject. Clostridium butyricum M1 release a Clostridium butyricum exosome. The Clostridium butyricum exosome could promote muscle growth of the subject. Bacillus coagulans CC212 release a Bacillus coagulans exosome. The Bacillus coagulans exosome and the Clostridium butyricum exosome could effectively reduce a fat mass of the subject. Therefore, the subject could experience an increase in muscle mass and a reduction in fat after taking the composition.

A fat mass composition and a method for producing the fat mass composition, the fat mass composition containing granules containing an oil or fat having a melting point of 0.1 DEG C or higher and an edible ionically-crosslinkable polymer that is cationically crosslinked, the granules having an average particle diameter of 50 [mu] m or more and 500 [mu] m or less and a swelling degree of 50% or more and 110% or less.

The application provides a brown fat recognition method and recognition device based on plain CT images, and solves the technical problem that the recognition cost and recognition accuracy of the existing brown fat recognition cannot be matched. The method comprises the following steps: establishing a tissue feature recognition model of brown fat by using the image features of the brown fat in the plain CT image resources; identifying the brown fat in the to-be-detected plain CT image according to the tissue feature recognition model, and quantifying the physical properties of the brown fat. The tissue feature recognition model is mainly trained or optimized by using low-cost plain CT image data, so that the brown fat and white fat can be effectively distinguished. The application provides a basic tool for target point recognition and tissue quantification, so as to explore how to activate the brown fat tissue in the human body through drugs, nutrition and other means, and to expect to find new strategies for treating obesity and diabetes.

The present invention relates to compositions and methods for altering body composition in an individual, wherein the alteration in body composition is both an increase in muscle mass and a decrease in fat mass. The present invention also relates to compositions and methods for decreasing fat mass in an individual. The compositions and methods also increase muscle volume and lean body mass in an individual. The present invention also relates to compositions comprising a GDF8 inhibitor and an activin A inhibitor, and the use of such compositions to treat diseases and conditions characterized by increased fat mass and / or decreased muscle volume.

The application of nitrone compounds in the preparation of a product for preventing or treating side effects caused by drugs for preventing or treating obesity. Animal experiments show that the use of nitrone compounds in combination with glucagon-like peptide-1 drugs not only does not affect the ability of glucagon-like peptide-1 drugs to reduce the fat mass of mice, but also can resist / attenuate the side effects of glucagon-like peptide-1 drugs; and after stopping the use of glucagon-like peptide-1 drugs, continuing to administer nitrone compounds can delay the speed of weight rebound after drug withdrawal, especially the speed of fat mass rebound. The nitrone compounds of the application can effectively prevent or treat the side effects of glucagon-like peptide-1 drugs, and have important clinical significance.